Skip to main content

Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials.

Sathian, B., Asim, M., Banerjee, I., Roy, B., Pizzaro, A., Mancha, M., van Teijlingen, E., Varkanesh, H., Mekkodathil, A., Subramanya, S.H., Nascimento, I., Antony, N., Menezes, R.G., Simkhada, P. and Al Hamid, H., 2021. Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials. Nepal Journal of Epidemiology, 11 (1), 959 - 982.

Full text available as:

[img]
Preview
PDF
Vaccines and sideeffects NJE 2021.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

1MB

Official URL: https://www.nepjol.info/index.php/NJE/article/view...

DOI: 10.3126/nje.v11i1.36163

Abstract

Background: To date, there is no comprehensive systematic review and meta-analysis to assess the suitability of COVID-19 vaccines for mass immunization. The current systematic review and meta-analysis was conducted to evaluate the safety and immunogenicity of novel COVID-19 vaccine candidates under clinical trial evaluation and present a contemporary update on the development and implementation of a potential vaccines. Methods: For this study PubMed, MEDLINE, and Embase electronic databases were used to search for eligible studies on the interface between novel coronavirus and vaccine design until December 31, 2020. Results: We have included fourteen non-randomized and randomized controlled phase I-III trials. Implementation of a universal vaccination program with proven safety and efficacy through robust clinical evaluation is the long-term goal for preventing COVID-19. The immunization program must be cost-effective for mass production and accessibility. Despite pioneering techniques for the fast-track development of the vaccine in the current global emergency, mass production and availability of an effective COVID-19 vaccine could take some more time. Conclusion: Our findings suggest a revisiting of the reported solicited and unsolicited systemic adverse events for COVID-19 candidate vaccines. Hence, it is alarming to judiciously expose thousands of participants to COVID-19 candidate vaccines at Phase-3 trials that have adverse events and insufficient evidence on safety and effectiveness that necessitates further justification.

Item Type:Article
ISSN:2091-0800
Uncontrolled Keywords:Coronavirus ; covid ; Covid-19 ; Vaccinations ; vaccines ; systematic review
Group:Faculty of Health & Social Sciences
ID Code:35356
Deposited By: Unnamed user with email symplectic@symplectic
Deposited On:06 Apr 2021 14:33
Last Modified:17 Aug 2021 21:24

Downloads

Downloads per month over past year

More statistics for this item...
Repository Staff Only -